Use of physiologically based kinetic modeling-facilitated reverse dosimetry to predict in vivo acute toxicity of tetrodotoxin in rodents

Annelies Noorlander*, Mengying Zhang*, Bennard van Ravenzwaay*a,b, Ivonne M.C.M. Rietjens*a

Division of Toxicology, Wageningen University, Stippeneng 4, 6708 WE Wageningen, the Netherlands

Experimental Toxicology and Ecology, BASF SE, Z 470, 67056 Ludwigshafen, Germany

*Corresponding author

Address: Division of Toxicology, Wageningen University, Stippeneng 4, 6708 WE Wageningen, the Netherlands

Email address: annelies.noorlander@wur.nl

ORCID ID: 0000-0003-2700-9390

Key words: Physiologically based kinetic modeling; reverse dosimetry; tetrodotoxin (TTX), neurotoxicity; new approach methodology

Running head: Predicting tetrodotoxin neurotoxicity by QIVIVE
Abstract

In the present study the ability of a new in vitro / in silico quantitative in vitro – in vivo extrapolation (QIVIVE) methodology was assessed to predict the in vivo neurotoxicity of tetrodotoxin (TTX) in rodents. In vitro concentration-response data of TTX obtained in a multielectrode array assay with primary rat neonatal cortical cells and in an effect study with mouse neuro-2a cells were quantitatively extrapolated into in vivo dose-response data, using newly developed physiologically based kinetic (PBK) models for TTX in rats and mice. Incorporating a kidney compartment accounting for active renal excretion in the PBK-models proved to be essential for its performance. To evaluate the predictions, QIVIVE derived dose-response data were compared to in vivo data on neurotoxicity in rats and mice upon oral and parenteral dosing. The results revealed that for both rats and mice the predicted dose-response data matched the data from available in vivo studies well. It is concluded that PBK modeling-based reserve dosimetry of in vitro TTX effect data can adequately predict the in vivo neurotoxicity of TTX in rodents, providing a novel proof-of-principle for this methodology.

Introduction

Tetrodotoxin (TTX) (fig. 1) is a naturally occurring neurotoxin that can be found in various marine gastropods and some fish species (Bane et al. 2014; Control and Prevention 1996). There are over 30 structural analogues of TTX (Huang et al. 2008). TTX has potent voltage gated sodium channel blocker activity (Sui et al. 2002), preventing depolarization and propagation of action potentials in nerve cells, resulting in the loss of sensation (Bane et al. 2014).

The acute exposure to TTX leads to a wide range of acute adverse effects including skeletal muscle fasciculations, apathy, lethargy, ataxia, paralysis and even death (Bane et al. 2014).

The European Food Safety Authority (EFSA) established an acute reference dose (ARfD) for TTX of 0.25 µg/kg bw based on an acute toxicity study with a single intragastric dose in mice with a no observed adverse effect level (NOAEL) of 75 µg/kg bw choosing apathy as the critical effect observed at a lowest observed adverse effect level (LOAEL) of 125 µg/kg bw (Abal et al. 2017; EFSA et al. 2017). In this study, lethality was observed at 250 µg/kg bw with a steep dose-response curve from which a BMDL\textsubscript{10} of 112 µg/kg bw could be derived (EFSA et al. 2017).

Because this BMDL\textsubscript{10} value for lethality was considered to be close to the NOAEL for apathy, the EFSA Panel argued that it cannot be excluded that effects can still occur at 75 µg/kg bw. Therefore, they established the ARfD based on the next lower test dose (25 µg/kg bw) using an uncertainty factor of 100 to derive the ARfD of 0.25 µg/kg bw. The EFSA opinion also provided an overview of LD\textsubscript{50} data from mouse studies upon different routes of exposure,
indicating toxicity upon oral gavage or intragastric dosing, with LD\textsubscript{50} values amounting to 232 µg/kg bw (Abal et al. 2017) and 532 µg/kg bw (Xu et al. 2003), to be substantially lower than the LD\textsubscript{50} values reported upon intraperitoneal or subcutaneous dosing, for which LD\textsubscript{50} values ranged from 9-12.5 µg/kg bw (Kao 1966; Kao and Fuhrman 1963; Marcil et al. 2006; Xu et al. 2003). In addition, the LD\textsubscript{50} in rats upon intramuscular administration was reported to amount to 10 - 11.1 µg/kg bw (Hong et al. 2017; Marcil et al. 2006), while Finch et al. (2018) and Hong et al. (2018) reported LD\textsubscript{50} values for rats upon oral dosing of 909 µg/kg bw and 571.43 µg/kg bw, respectively, that were not included in the EFSA overview.

The available TTX data for human are too limited to provide a point of departure (PoD) for risk assessment, with only a minimum lethal oral dose of 2 mg being mentioned in literature, which is equivalent to 40 µg/kg bw for a 50 kg Japanese subject (EFSA et al. 2017). Additionally, Kasteel and Westerink (2017) proposed an ARfD of 1.33 µg/kg bw for human based on a so-called universal mammalian LD\textsubscript{50} of 400 µg/kg bw derived from reported oral LD\textsubscript{50} values in mice (334-700 µg/kg bw). They applied a conservative factor of 10 to go from an LD\textsubscript{50} value to a LOAEL value (40 µg/kg bw) and added another factor of 3 to obtain a NOAEL value (13.3 µg/kg bw). Finally, they took a factor of 10 into account for intraspecies differences.

Given the available data sets on acute toxicity of TTX in rodents and the many analogues of TTX for which experimental toxicity data are lacking, it is of interest to study whether the acute toxicity of TTX can be adequately predicted by a new approach methodology (NAM) such as quantitative in vitro in vivo extrapolation (QIVIVE) using physiologically based kinetic (PBK) modeling with integrated in vitro and in silico data and applying reverse-based dosimetry. Thus, the present study aimed to evaluate the potential of using in vitro toxicity data obtained with primary rat neonatal cortical cells on a multielectrode array (MEA) assay or an effect study in mouse neuro-2a cells combined with PBK model based-reverse dosimetry to predict the in vivo acute neurotoxicity of TTX in rodents. As TTX is hardly metabolized, highly hydrophilic and has been identified as a substrate for organic cation transporters in the kidneys (Matsumoto et al. 2017), active renal transport can be expected to contribute substantially to the in vivo TTX kinetics and has to be accounted for in the PBK models to be developed to facilitate the QIVIVE.

### Materials and Methods

#### Materials

Tetrodotoxin ≥ 98% (TTX, CAS 4368-28-9), was purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). Dimethyl sulfoxide (DMSO) was purchased from Acros Organics (Geel, Belgium) and phosphate-buffered saline
(PBS) was purchased from Invitrogen (Breda, the Netherlands). Pooled hepatocytes from male Sprague-Dawley rats, cryopreserved hepatocyte recovery medium (CHRM, CM7000), and primary hepatocytes thawing and plating supplements (CM4000) were purchased from Thermo Fisher (Landsmeer, the Netherlands).

**Methods**

1. **Clearance of TTX**

It was assumed that the in vivo acute toxicity of TTX is induced by the parent compound as there is no evidence of potential metabolites exerting a similar effect. Therefore, only the overall hepatic clearance of TTX was included in the PBK model. Primary hepatocytes from male Sprague-Dawley rats were used to determine the hepatic clearance by the substrate depletion approach. To this end, pooled primary hepatocytes were thawed in a 37°C water bath and transferred to 50 ml cryopreserved hepatocyte recovery medium (CHRM, CM7000). The cell suspension was centrifuged at 100×g for 15 min at room temperature, and the supernatant was removed. The collected hepatocytes were dissolved in 1 ml pre-warmed hepatocyte incubation medium, which contained 4% primary hepatocyte thawing and plating supplements (CM4000) in Williams’ Medium E1 without phenol red. The density and viability of the hepatocytes were measured using the Cellometer (Auto T4, Nexcelom Bioscience). Hepatocytes with more than 90% viability were used for the incubation. The cells were diluted with incubation medium to reach a density of 1×10^6 cells/ml. TTX was dissolved in DMSO to obtain a stock solution of 600 µM. 20 µl Stock solution of TTX was added to 1980 µl medium to generate the exposure medium (final DMSO concentration 1% v/v). The exposure medium was pre-incubated for 5 min. The incubation was started by adding 100 µl primary hepatocytes into 100 µl pre-incubated exposure medium, giving a final concentration of 0.5×10^6 cells/ml and 3 µM TTX (a non-toxic concentration to hepatocytes as shown by the WST-1 assay (data not shown)) (final DMSO concentration 0.5% v/v). The incubation was done using a shaker (Titramax 1000, Heidolph, Germany) at 150 rpm in a 5% CO₂, 95% air-humidified incubator. The incubation time points were: 0, 1, 2, 3, 4, 5, 7, 8.5, 10, 15, 30, 45, 60 and 90 min. For each incubation time point a corresponding control was included, consisting of an incubation performed in the absence of primary hepatocytes. The incubation was terminated by adding 100 µl cold acetonitrile and the samples were put on ice for 30 min, then centrifuged at 3500 rpm (1200 g) for 15 min at 4°C. Supernatants were collected and the concentration of TTX was quantified using LC-MS/MS analysis. All incubations were performed in triplicate in three independent studies. The ratio of the remaining parent compound concentration in the incubation sample (C_{compound}) and in the sample at time 0 as control (C_{control}) was calculated for each incubation time (taking the amount of TTX left in the corresponding control incubations into account) and the depletion curve of the parent compound
(\ln(C_{\text{compound}}/C_{\text{control}})) \text{ against time} \text{ was derived. The slope of the linear part of the depletion curve represents the}
elimination rate constant (k, in 1/min) of the parent compound. The in vitro clearance (CL_{\text{int, in vitro}}) of the parent
compound was calculated using the following equation: CL_{\text{int, in vitro}} (\text{ml/min}/10^6 \text{ cells}) = k (1/min)/ V (10^6 \text{ cells/ml})
(Obach 1999; Sjögren et al. 2009). V represents the number of hepatocytes per ml incubation mixture, (0.5\times10^6
\text{ cells/ml}). The in vitro CL_{\text{int}} of the parent compound was scaled to a whole liver using the scaling factor of 135,000
(cell density liver expressed in 10^6 \text{ cells/kg}) (Houston 1994).

2. Analysis of TTX by LC-MS/MS

LC-MS/MS analysis was performed on a Shimadzu Nexera XR LC-20AD SR UPLC system coupled with a
Shimadzu LCMS-8045 mass spectrometer (Shimadzu Benelux, ‘s Hertogenbosch, the Netherlands). The samples
(1\mu l) were loaded onto a BEH C18 column (1.7 \mu m, 2.1\times100 \text{ mm}) at a flow rate of 0.3 \text{ ml/min}. The column
temperature was set to 40 °C. The mobile phase consisted of ultrapure water with 0.1% (v/v) formic acid as mobile
phase A and acetonitrile containing 0.1% (v/v) formic acid as mobile phase B. The initial condition of the eluents
was 5% A, then changed to 50% A in 2 min and subsequently returned to the initial condition in the next 5 min, and
was kept at these starting conditions for another 5 min. The total runtime was 12 min. A Shimadzu LCMS-8045 triple
quadrupole with electrospray ionization (ESI) interface was used to perform the MS-MS analysis. The instrument
was operated in the positive ion mode in the multiple reaction monitoring (MRM) mode with a spray voltage of 4.5
kV. TTX was monitored at the [M+H]^+ \text{ of precursor to product 320.1>302.19, 320.1>162.4 and 320.1>60.2 m/z}. The
Postrun Analysis function from the LabSolutions software (Shimadzu, Kyoto, Japan) was used to obtain the peak
area of the total ion chromatogram (TIC).

3. Development of the PBK model for TTX

The generic PBK model developed in our previous study (Zhang et al. 2019) was used with minor modifications,
defining a PBK model for TTX in both rat and mouse. To allow model evaluation based on the three available in vivo
kinetic data sets, all with different administration routes, the PBK model was built for oral, intravenous (IV) and
intramuscular (IM) administration (Hong et al. 2017; Hong et al. 2018). For the IM administration it was assumed
that TTX was solely taken up in the blood via the muscle tissue at the injection site, thereby excluding the role of the
subcutaneous and lymph routes. To distinguish between IM and IV administration the rate of absorption from the IM
injection site was set to a much lower value (50 hr^{-1}) than that for an IV injection (1000,000 hr^{-1}). Given that the study
by Hong et al. (2017) concluded that the predominant route of the elimination of TTX is by urinary excretion, a kidney compartment was included in the PBK models. The developed PBK model for TTX consisted of eight compartments, including the site of injection, GI-tract, blood, fat, liver, kidney, rapidly perfused tissue and slowly perfused tissue. The schematic representation of the PBK model is displayed in figure 2. A separate compartment for the brain was not included given the inability of TTX to pass the blood brain barrier (Melnikova et al. 2018). The values for physiological and anatomical parameters for rat were obtained from Brown et al. (1997b) and for mouse from Hall et al. (2012). The partition coefficients to describe the distribution of TTX over the different tissues were estimated using the quantitative property-property relationship (QPPR) approach from Rodgers and Rowland (2006) facilitated by a QIVIVE toolbox (input: zwitterion, pKa1: 8.76, pKa2: 11 logP: -6.2 and molecular weight: 319.27 g/mol) (Punt et al. 2020). The assumption was made that the distribution of TTX in rat is the same as in mouse. The glomerular filtration (GF) was added to the model according to the equation: GF = GFR × (CVK × fub\textsubscript{in vivo}), where GFR is the glomerular filtration rate, which is 5.2 ml/min/kg bw for rat and 14 ml/min/kg bw for mouse (Walton et al. 2004), CVK is the concentration of TTX in the kidney compartment and fub\textsubscript{in vivo} is the fraction of TTX unbound in the in vivo situation. As mentioned by Matsumoto et al. (2017), TTX seems to be a substrate for some active transporters in the proximal tubule cells in the kidney. Since it is unknown which transporter has the highest contribution it was decided to work with an estimated apparent overall V\textsubscript{max} and K\textsubscript{m}; one V\textsubscript{max} and one K\textsubscript{m} for all transporters involved. After running model predictions including only glomerular filtration as the excretion pathway, data for the apparent overall V\textsubscript{max} and K\textsubscript{m} were estimated based on manual input of V\textsubscript{max} and K\textsubscript{m} searching for the optimal transporter efficiency (TE = V\textsubscript{max}/K\textsubscript{m} in µl/min/mg protein) by fitting to the available in vivo kinetic data. Matsumoto et al. (2017) reported Papp values for the bidirectional transport of TTX over an LLC-PK1 kidney cell layer. Future use of such Papp values to define the in vivo kinetic parameters for urinary excretion of TTX in a PBK model requires definition of the scaling factor(s) needed to convert these in vitro Papp values to the kinetic constants for active transport of TTX in the kidney in vivo. This scaling could be achieved by scaling the model predictions to fit available in vivo data, as done in the present study for V\textsubscript{max}, as well as in other studies for other transport parameters, including parameters for renal excretion in PBK models, such as for the PBK model for perfluorooctanoic acid (PFOA) in rats (Worley and Fisher 2015) and the PBK model for mepiquat in rats (Noorlander et al. 2021). The model equations were coded and numerically integrated in Berkeley Madonna 8.0.1 (UC Berkeley, CA, USA), using the Rosenbrock’s algorithm for stiff systems (see supplementary materials A for the model codes).
4. PBK model evaluation

For evaluation of the PBK model, in vivo kinetic data of the TTX blood concentration in time upon oral, IV or IM dosing were available for rats (Hong et al. 2017; Hong et al. 2018). It was assumed that evaluation of the model in rats would support its use for mice as well. It is important to note that the in vivo kinetic data were obtained in plasma, whereas the PBK model predicts the concentration in whole blood. Thus, an adjustment of the reported concentrations in plasma to concentrations in blood was made by multiplying the plasma data with the blood:plasma ratio (0.42; derived from Hong et al. (2017). For the IM administration kinetic data presented by Hong et al. (2017) for the dried plasma curve were used since these data were corrected for the formed tritiated water by the hydrogen-tritium exchange of 11-[3H]TTX in the plasma possibly interfering with the results. To identify the most influential parameters of the PBK model on the model prediction of the maximum blood concentration \(C_{\text{max}}\) upon oral and IM administration, a sensitivity analysis was performed (see figure S1 of supplementary materials B). To this end, an initial input parameter value was increased by 5% and the sensitivity coefficients (SC) were calculated using the equation \(SC = \frac{(C' - C)}{(P' - P)} \times \frac{(P)}{(C)}\), in which \(P\) and \(P'\) represent the initial and modified parameter value respectively, while \(C\) and \(C'\) are the initial and modified model output for \(C_{\text{max}}\) (Evans and Andersen 2000). Each parameter was analyzed individually by changing one parameter at a time keeping the other parameters at their original value, while the total blood flow fraction was kept as 1. The sensitivity analysis was performed for exposure to 6 µg/kg for the oral and IM routes, representing the dose level actually used in the available in vivo studies (Hong et al. 2017; Hong et al. 2018).

5. Translation of the in vitro neurotoxicity data for TTX to in vivo dose response data

For rat, two in vitro concentration-response data sets were available. Both studies performed the multielectrode array (MEA) assay using primary rat neonatal cortical cells for measuring neuronal activity upon exposure to TTX (Kasteel and Westerink 2017; Nicolas et al. 2014). For mouse, four in vitro concentration-response data sets were available, where in all studies mouse neuro-2a cells were used to detect the inhibition by TTX on cellular toxicity (Hamasaki et al. 1996; Kogure et al. 1988; Nicolas et al. 2015; Yamashoji and Isshiki 2001; Yeo et al. 1996). The inhibition is induced by first exposing the cells to veratridine (sodium channel opener) and ouabain (blocking of Na⁺/K⁺-ATPase) which may result in disturbance of the sodium ion homeostasis in the cells resulting in cell death (Kogure et al. 1988; Rossini and Hartung 2012). When the veratridine/ouabain-treated cells are exposed to TTX the sodium channels are blocked and sodium accumulation in the cells is prevented, counteracting the toxic effects of veratridine and ouabain.
thereby leading to cell survival (Kogure et al. 1988). Throughout the present study this assay is further referred to as the neuro-2a assay. The available concentration-response data were used to predict the dose levels that were required to reach the respective effect concentrations of TTX in blood, using PBK modeling-based reverse dosimetry. It is of importance to realize that only the free fraction of the compound will exert the effects, which implies that a correction for protein binding prior to applying reverse dosimetry should be considered. However, due to the physicochemical characteristics of TTX the fraction unbound in vivo is 1 (see toolbox Punt et al. (2020)) and therefore, given the excellent water solubility of TTX, it was assumed that in the in vitro MEA medium and neuro-2a medium containing 10% fetal bovine serum the $f_{u_{in\,vivo}}$ of TTX was 1, too. Thus, the in vitro effect concentration ($EC_{in\,vivo}$) of TTX was set equal to an in vivo effect concentration ($EC_{in\,vivo}$), without a need for correction for potential differences in protein binding in the in vitro and in vivo situation. The $C_{\text{max}}$ was the chosen dose metric for reverse dosimetry of TTX as the mode of action of its toxicity, sodium channel blocking, shows to be a concentration-dependent endpoint with a threshold (Rietjens et al. 2019). So, the estimated $EC_{in\,vivo}$ was set equal to $C_{\text{max}}$ of TTX in the PBK model. By repeating these steps for all the in vitro test concentrations, the in vitro concentration-response data were converted to define the corresponding in vivo dose-response data.

6. Comparing predicted dose-response curves to in vivo toxicity data

After evaluation of the model the predicted in vivo dose-response curves were compared to the available in vivo TTX toxicity data. For this comparison the most sensitive endpoint for toxicity was chosen for each route and species as described in the result section. To quantify the comparison benchmark dose (BMD) responses were generated using the EFSA online BMD software. The $BMD_{10}$ and $BMDL_{10}$ were determined under the EFSA default settings for Akaike information criterion (AIC) being 2 and a confidence interval of 95%. Only $BMD_{10}$ and $BMDL_{10}$ values as a result of model averaging were taken. Furthermore, a medium effective dose (and concentration) ($ED_{50}$ and $EC_{50}$) was calculated in Excel using the TREND function as follows: 1) calculate from the dataset the halfway response: $\frac{\text{lowest } y_{\text{value}} + \text{(highest } y_{\text{value}} - \text{lowest } y_{\text{value}})/2}{2}$ and 2) use the TREND function, which includes the 2 $x$-values with corresponding $y$-values in between where the halfway response lies to calculate its $x$-value, also the $ED_{50}$ (or $EC_{50}$). $EC_{50}$ values were used to compare the in vitro data sets.

7. Human model
In spite of the limited available human data on TTX kinetics, a human PBK-model was defined, assuming that the
evaluation of the model in rat would support its use for humans. The physiological and physicochemical parameters
for the human model were taken from the literature in a similar way as for rat (Brown et al. 1997a; Punt et al. 2020)
and are presented in Table 1. The kinetic constants were taken from the rat model and adjusted to human using
human scaling factors. For reverse dosimetry one in vitro data set was available (Kasteel and Westerink 2017)
describing a concentration response curve for the effect of TTX on human-induced pluripotent stem cell (hPSC)-
derived iCell® neurons in co-culture with hPSC-derived iCell® astrocytes in the MEA assay. Using our human PBK-
model, this in vitro concentration-response curve was translated to an in vivo dose-response curve for oral exposure
to TTX and a BMD<sub>10</sub>, BMDL<sub>10</sub> and ED<sub>50</sub> were derived that were compared to available (on mouse study based)
human data on TTX toxicity.

**Results**

**Substrate depletion of TTX**

Figure 3 shows the depletion of TTX in incubations with rat hepatocytes. The in vitro hepatic clearance (CL<sub>int</sub>) derived
from these data amounted to 1.6×10<sup>-7</sup>±0.01 ml/min/10<sup>6</sup> cells converted to an in vivo CL<sub>int</sub> of 1.1×10<sup>-5</sup> L/hr for the
rat, indicating that clearance of TTX via metabolism is limited. It was assumed that the mouse hepatic clearance
would be similarly limited.

**In vitro concentration-response data for TTX in rodent cells**

The available in vitro concentration-response data for neurotoxicity of TTX in rat primary neonatal cortical cells in
the MEA assay and for the neurotoxicity of TTX in the mouse neuro-2a assay are summarized in figure 4. Both the
rat MEA data (Fig. 4a) and the mouse neuro-2a data (Fig. 4b) reported in different studies provide comparable results,
except for the data of Nicolas et al. (2015) for the mouse neuro-2a assay, which indicate at a somewhat greater
sensitivity. Nevertheless, these data together provide a suitable data set for QIVIVE and conversion into in vivo dose-
response curves. Given the similarity of the concentration-response curves for the TTX induced neurotoxicity in the
neuro-2a assay reported in the studies of Hamasaki et al. (1996), Yamashoji and Isshiki (2001) and Yeo et al. (1996)
these three data sets were used for the mice predictions by reverse dosimetry. The graphs in figure 4 show that the rat
primary neonatal cortical cells in the MEA assay (EC<sub>50</sub> values 0.0035 µM and 0.0055 µM) (Figure 4a) seem to be
only slightly more sensitive than the mouse neuro-2a cells in the neuro-2a assay (EC<sub>50</sub> values of the 3 corresponding
data sets amounting to 0.0082 µM).

**PBK model evaluation**

The evaluation of the PBK model using different routes of administration and the parameter input presented in table
1 is shown in figure 5. Predictions were fitted to the in vivo data by estimating the rate of absorption for the oral route
(ka: 0.18/hr) and IM route (kb: 50/hr) and optimizing the contribution of active renal excretion based on the
transporter efficiency, which was 90 µl/min/mg protein (V<sub>max</sub> = 180 pmol/min/mg protein, Km = 2 µM). It appeared
important to include this active excretion since it accounts for a substantial improvement in the predictions (compare
figure 5 with renal excretion, to figure S2 in the supplementary materials B for data without taking renal excretion
into account). For all administration routes, oral (fig. 5a) IM (fig. 5b) and IV (fig. 5c), the model was able to
adequately predict the in vivo data. To enable subsequent PBK model-based reverse dosimetry for both the oral and
the IM mode of administration a plot of the dose against C<sub>max</sub> was made, which was used to convert the in vitro
concentrations from figure 4 to in vivo dose levels to generate the dose-response curves. As explained in the materials
and methods section, the high water solubility of TTX eliminated the need for a correction for differences in protein
binding with the fub in vitro and in vivo both being 1.

**Literature reported in vivo dose-response data in rodents**

Figure 6 summarizes the available in vivo dose-response data for TTX in rodents available in literature for evaluation
of the QIVIVE predictions. It must be noted that although the reported in vivo data are used for evaluation of the
QIVIVE predictions made in the current study using a NAM, this does not imply that the authors of the present study
agree with the ethics of these animal studies as they involve pain and discomfort to the animals. Three data sets for
rat (fig. 6a) originate from studies reporting on the pharmacological application of TTX as a morphine-like painkiller
(Kohane et al. 2000; Kohane et al. 1998; Marcil et al. 2006). The dose response curves from these three studies reveal
substantial differences in sensitivity depending on the endpoint used to quantify the effect. The data reported by
Marcil et al. (2006) using the so-called Von Fray hair test to quantify the TTX induced reduction in mechanical
allodynia (pain) showed effects at 16-fold lower dose levels (fig. 6a left y-axis) than the dose response curves defined
based on TTX induced thermal nociceptive blocking (blocking of the peripheral sensory neurons; nociceptors) (fig.
6a right y-axis). The route of administration in all three studies was comparable consisting of
subcutaneous/percutaneous injection. The data set reporting mechanical allodynia, apparently relating to the most sensitive endpoint, was selected for QIVIVE-based predictions. For mouse (fig. 6b), six data sets were identified in the available literature of which two related to parenteral administration and four to oral administration (Abal et al. 2017; Finch et al. 2018; Marcil et al. 2006). Here too, the data sets for the parenteral route differ markedly, as the endpoint ‘time to death’ in minutes requires higher doses to be affected than the more sensitive endpoint including a so-called writhing test where the number of contractions of the abdomen was measured after exposure to acetic acid following increasing concentrations of TTX (both shown on left y-axis of figure 6b). The latter study was selected for further QIVIVE-based predictions. The data sets for the oral route show a lower sensitivity to TTX compared to the parenteral route likely related to the low oral bioavailability of TTX of 6.7% reported by Hong et al. (2018). For the oral route, dose-response curves for the macroscopically observed neurological symptoms apathy, numbness, seizures and mortality were available (shown on right y-axis of figure 6b), where apathy was the most sensitive endpoint and therefore selected for the QIVIVE-based predictions.

QIVIVE to translate in vitro neurotoxicity data for TTX into in vivo dose response data

The in vitro concentration response curves were translated to in vivo dose response curves using the PBK models for reverse dosimetry and QIVIVE. This resulted in the predicted dose response curves presented in figure 7 on the left y-axis. This figure also presents, for comparison, the reported in vivo dose response curves for the most sensitive endpoint as taken from figure 6a on the right y-axis. The results thus obtained reveal an adequate match between the predicted and actual experimentally obtained dose response curves, with the predicted ED$_{50}$ values differing only 1–1.4-fold from the in vivo ED$_{50}$ value (Table 2).

For mouse, both the IM model and the oral PBK model were used to translate the respective in vitro concentration-response data into in vivo dose-response data (fig. 8). For the parenteral route, the most sensitive endpoint was the number of visceral contractions for which the in vivo dose-response curve was provided by Marcil et al. (2006). Figure 8a presents a comparison of the in vivo experimental data (right y-axis) to the predicted dose-response curves (left y-axis) for TTX in mice. This comparison reveals that the predicted dose-response curves based on the in vitro data obtained in the neuro-2a assay are in line with the observed in vivo dose-response data as the predicted ED$_{50}$ values varies 1.8-fold to a maximum of 3-fold from the in vivo ED$_{50}$ value (Table 2). Apathy was the most sensitive endpoint for the oral route and therefore chosen for the comparison to the predicted dose-response curve upon oral
administration of TTX (fig. 8b). Here too, the predicted dose-response curves (left y-axis) appear to be in accordance with the observed in vivo data (right y-axis) with the predicted ED$_{50}$ values being at most up to 2.3-fold lower than the observed in vivo ED$_{50}$ value (Table 3).

**Predicting TTX neurotoxicity in human and estimating a tentative point of departure**

Upon evaluation of the rat TTX model the model code was used to define a human oral PBK-model. For predicting TTX neurotoxicity in human by QIVIVE an in vitro data set reported by Kasteel and Westerink (2017) was used describing TTX toxicity towards human IPSC-derived iCell® neurons in co-culture with hIPSC-derived iCell® astrocytes exposed to TTX in the MEA (multielectrode array assay) (fig. 9a). The dose-response curve obtained of TTX in this MEA cell model was translated to an in vivo dose-response curve applying PBK model based reverse-dosimetry with the human PBK-model resulting in an in vivo dose response curve with an ED$_{50}$ of 18 µg/kg bw (fig. 9b). Further BMD analysis on this predicted in vivo dose response curve resulted in a BMD$_{10}$ of 4.3 µg/kg bw, and a BMDL$_{10}$ of 1.8 µg/kg bw (See supplementary materials B, Figure S3 and S4 and Table S1 for details). Taking the BMDL$_{10}$ as a point of departure for the risk assessment of TTX and using a factor 10 for interindividual variability would result in an Acute Reference Dose (ARfD) of 0.18 µg/kg bw. This tentative point of departure is only 1.4-fold different from the previously established ARfD by EFSA of 0.25 µg/kg bw based on an acute toxicity study in mice (Abal et al. 2017).

**Discussion**

TTX is an acute neurotoxin, which upon systemic exposure affects both action potential generation and impulse conduction by extracellular blockade of the voltage gated sodium channels. The available acute reference dose (ARfD) of TTX (0.25 µg/kg bw), is derived from a study on mice in which TTX was dosed orally (via gavage) (EFSA et al. 2017). Given the available data sets on acute toxicity of TTX in rodents and the many analogues of TTX for which experimental toxicity data are lacking, it is of interest to study whether the acute toxicity of TTX can be adequately predicted by a new approach methodology (NAM) based on in vitro and in silico data.

PBK modeling based reverse dosimetry has proven to be a promising NAM to derive quantitative data, which can potentially be used in risk assessment to estimate in vivo toxicity in rodents and human (Chen et al. 2018; Li et al. 2017a; Louisse et al. 2014; Ning et al. 2019; Shi et al. 2020; Strikwold et al. 2017; Zhang et al. 2018; Zhang et al.
The present study aimed to assess the potential of using the PBK modeling-based reverse dosimetry approach as a NAM to predict the neurotoxicity of TTX in rodents, based on in vitro toxicity data obtained in the MEA assay using primary rat neonatal cortical cells or data obtained using the mouse neuro-2a assay.

Evaluation of the PBK model performance for TTX demonstrated its adequacy for predicting kinetic data for different routes of administration. In line with the results from Hong et al. (2017) who reported that less than 10% of TTX was metabolized, the results of the present study corroborated that hepatic metabolism does not contribute substantially to the systemic clearance of TTX (in vitro $CL_{int}$: $1.6 \times 10^{-7} \pm 0.01$ ml/min/10⁶ cells; in vivo $CL_{int}$: $1.15 \times 10^{-5}$ L/hr), while renal excretion plays a major role in TTX kinetics. Furthermore, the PBK modeling data of the present study revealed that up to 86% of TTX clearance in the kidney could be ascribed to active transport by the proximal tubule cells. This active transport of TTX was previously also demonstrated in the renal proximal tubule cell line LLC-PK1 (Matsumoto et al. 2017). In this in vitro study, TTX was shown to be primarily transported by the organic cation transporters and the organic cation/carnitine transporters. To a lesser extent organic anion transporters and multidrug resistance-associated proteins were involved, too. The PBK model evaluation of the present study provides insight in the efficiency of this active transport and revealed that it contributes considerably to TTX clearance. To substantiate the values used in this paper it would be of interest to perform in vitro transport studies with TTX for the organic cation transporters in stably transfected cell lines such as the human embryonic kidney cell line HEK-293 and investigate to what extent such in vitro data can provide the kinetic data defined in the present study by fitting the PBK model to available in vivo data for TTX kinetics.

The results obtained revealed that the NAM used in this study could adequately predict the dose-response curves for the selected most sensitive endpoints reported in the available in vivo studies. This, in spite of the fact that the spike rates used as readout in the MEA assay (Nicolas et al. 2014) and the endpoint quantified in the MTT assay using the mouse neuroblastoma cell line, both used to generate the in vitro concentration-response curves, may detect TTX neurotoxicity based on different endpoints than the endpoints quantified in the in vivo neurotoxicity studies. This is possible because the underlying mode of action for all in vivo endpoints relates to the TTX mediated blocking of sodium channels. The reasons underlying the differential sensitivity of the various in vivo endpoints may relate to as yet unidentified differences in the toxicodynamics and/or toxicokinetics of TTX in the target tissue of interest underlying the respective adverse effects (mechanical alldynia, thermal nociceptive blocking, visceral contractions, apathy, seizures).
So the question arises as to what extent the endpoints quantified in the MEA assay or the neuro-2a assay match these in vivo endpoints. Although the mechanism of action underlying all the in vitro and in vivo endpoints studied for TTX is blocking of the voltage-gated sodium channels, thereby interfering with the production of action potentials, it is of interest to consider the different endpoints in some more detail. For the rat in vivo data, the sensory neurons stimulated in the Von Frey hair test and the thermal nociceptive blocking test are non-visceral (or somatic) sensory neurons that can respond to (noxious) events such as mechanical, (extreme) heat/cold or chemical stimuli (Dubin and Patapoutian 2010; Robinson and Gebhart 2008). In both experiments the hind paw of the rats was exposed to either mechanical stimuli by Von Frey filaments or heat stimuli by a hot plate (56°C) until paw withdrawal was observed.

Apparently, enduring the pain of heat (uncomfortable sensation) requires higher doses of TTX than enduring the pinprick of a Von Frey filament until uncomfortable sensation, and the type of stimuli (mechanical, heat) and/or the underlying pathway determines how sodium channel blocking is perceived. Here, the Von Frey hair test seems to be the more sensitive endpoint than the thermal nociceptive blocking test. The underlying neuronal/neuromuscular processes to further explain this difference between the different in vivo endpoints lies beyond the scope of this study (Dubin and Patapoutian 2010).

In the MEA assay primary rat neonatal cortical neurons isolated from cortices form a network of inhibitory and excitatory cells with different subtypes and amongst them non-visceral neurons (Masland 2004; Nicolas et al. 2014; Schnitzler et al. 1999). In the MEA assay the neuronal cells are directly exposed to TTX and show a decrease in activity compared to baseline with increasing concentrations of TTX. The sodium channel block is therefore directly measurable, whereas this effect in vivo is only indirectly noticeable via neuromuscular communication with the central nervous system. Nevertheless, the MEA assay provides a very sensitive endpoint, therefore the in vivo endpoint chosen for the comparison to data predicted based on the in vitro assay should be as sensitive as possible.

A similar evaluation for in vitro endpoints and in vivo endpoints can be performed for the mouse assays. The in vivo data on mice, generated in the writhing test, are based on innervation of the visceral sensory neurons by exposure to acetic acid, which via the acid-sensing ion channels lead to pain sensation expressed as abdomen contraction together with twisting and turning of the trunk and arching of the back (Holzer 2011; Marcil et al. 2006; Robinson and Gebhart 2008). These effects are decreased by increasing TTX concentrations blocking the sodium channels and preventing signal transduction. This endpoint appears much more sensitive than measuring the time of death that requires higher doses of TTX (Finch et al. 2018). Comparing the endpoint of the TTX effect in the in vivo writhing test -decrease of visceral contractions- to the TTX effect in the in vitro neuro-2a assay-cell survival- suggests that these endpoints are not exactly the same in spite of the similar underlying mechanism of action. However, in spite of this apparent
difference, the use of the neuro-2a assay for QIVIVE did provide adequate in vivo predictions for the writhing test. Similarly, outcomes of the in vitro embryonic stem cells test (EST) for developmental toxicity, detecting the inhibition of the development of mouse embryonic ES-D3 stem cells to beating cardiomyocytes, appeared to provide a suitable in vitro endpoint to predict a wide range of in vivo endpoints for developmental toxicity including malformations, number of live pups and fetal body weight (Kamelia et al. 2017; Li et al. 2017b; Strikwold et al. 2013).

With respect to neurotoxicity, previous studies already concluded that for determining the toxicity of neurotoxins in vitro the two most promising assays are the MEA assay (using rat primary neonatal cortical cells) and the mouse neuro-2a assay (Bodero et al. 2018; Nicolas et al. 2015; Nicolas et al. 2014). The results of the present study reveal that these two assays are adequate to define concentration-dependent in vitro toxicity data for TTX for QIVIVE using PBK model based-reverse dosimetry. Moreover, using a human iPSC in vitro MEA assay showed to have potential to generate data for establishing a tentative point of departure (BMDL_{10}) for human TTX toxicity in line with the previously established ARfD by EFSA. To confirm this with more proof, more research should be conducted on the kinetics of TTX in human.

To recapitulate, in this study we have successfully built a PBK model for the marine biotoxin TTX in rodents (rat, mouse) where renal excretion via active transport seems to play a major role in its kinetics. The results presented provide support for the use of this NAM for predicting the acute neurotoxicity of TTX (and its analogues). Thereby, a cautious attempt has been made to predict TTX toxicity in human using only in vitro and in silico data applying reverse based dosimetry enabled by PBK-modeling and shows to have potential.

Declaration of conflicts of interest

The authors report no potential conflicts of interest.

Funding

This research was supported by BASF SE.
Reference


Nicolas J, Hendriksen PJ, de Haan LH, Koning R, Rietjens IM, Bovee TF. 2015. In vitro detection of cardiotoxins or neurotoxins affecting ion channels or pumps using beating cardiomyocytes as alternative for animal testing. Toxicol In Vitro. 29(2):281-288.


Table 1. Physiological and anatomical parameter values and the partition coefficients used for the PBK models

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Rat(^a)</th>
<th>Mouse(^b)</th>
<th>Human(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (kg)</td>
<td>0.24</td>
<td>0.03</td>
<td>70</td>
</tr>
<tr>
<td><strong>Fraction of tissue volumes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat</td>
<td>0.070</td>
<td>0.070</td>
<td>0.214</td>
</tr>
<tr>
<td>Liver</td>
<td>0.034</td>
<td>0.055</td>
<td>0.026</td>
</tr>
<tr>
<td>Blood</td>
<td>0.074</td>
<td>0.067</td>
<td>0.079</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.007</td>
<td>0.017</td>
<td>0.004</td>
</tr>
<tr>
<td>Rapidly perfused tissue</td>
<td>0.091</td>
<td>0.137</td>
<td>0.064</td>
</tr>
<tr>
<td>Slowly perfused tissue</td>
<td>0.724</td>
<td>0.654</td>
<td>0.613</td>
</tr>
<tr>
<td>Cardiac output</td>
<td>(15^1)</td>
<td>(15.4^2)</td>
<td>(15^1)</td>
</tr>
<tr>
<td><strong>Fraction of blood flow to tissue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat</td>
<td>0.070</td>
<td>0.070</td>
<td>0.052</td>
</tr>
<tr>
<td>Liver</td>
<td>0.174</td>
<td>0.158</td>
<td>0.227</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.141</td>
<td>0.114</td>
<td>0.175</td>
</tr>
<tr>
<td>Rapidly perfused tissue</td>
<td>0.093</td>
<td>0.516</td>
<td>0.195</td>
</tr>
<tr>
<td>Slowly perfused tissue</td>
<td>0.512</td>
<td>0.142</td>
<td>0.351</td>
</tr>
<tr>
<td><strong>Partition coefficients</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log(P_{ow})</td>
<td>-6.2(^d)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pKa1</td>
<td>8.76(^e)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pKa2</td>
<td>11(^e)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat/blood partition coefficient</td>
<td>0.46</td>
<td>0.46</td>
<td>0.46</td>
</tr>
<tr>
<td>Liver/blood partition coefficient</td>
<td>4.29</td>
<td>4.29</td>
<td>4.29</td>
</tr>
<tr>
<td>Kidney/blood partition coefficient</td>
<td>4.70</td>
<td>4.70</td>
<td>4.70</td>
</tr>
<tr>
<td>Rapid perfused tissue/blood partition coefficient</td>
<td>4.29</td>
<td>4.29</td>
<td>4.29</td>
</tr>
<tr>
<td>Slowly perfused tissue/blood partition coefficient</td>
<td>0.95</td>
<td>0.95</td>
<td>0.95</td>
</tr>
</tbody>
</table>

\(^a\) Brown et al. (1997a)

\(^b\) Hall et al. (2012)

\(^c\) Punt et al. (2020)

\(^d\) Hort et al. (2020)

\(^e\) Camougis et al. (1967)

\(^1\) L/hr×kg×bw\(^0.74\)

\(^2\) L/hr×kg×bw\(^0.75\)
Table 2. Established ED$_{50}$ values for the predicted in vivo dose-response data and in vivo data for rat and mouse via parenteral administration. The literature reported ED$_{50}$ values used for comparison to the predicted ED$_{50}$ values are printed in bold.

<table>
<thead>
<tr>
<th>ED$_{50}$ (µg/kg bw)</th>
<th>Endpoint</th>
<th>Literature</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Injection</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rat</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicted</td>
<td>1</td>
<td>MEA Spike</td>
</tr>
<tr>
<td></td>
<td>0.7</td>
<td>MEA Spike</td>
</tr>
<tr>
<td>In vivo</td>
<td><strong>0.7</strong></td>
<td>Von Frey</td>
</tr>
<tr>
<td></td>
<td>10.4</td>
<td>Nociceptive block</td>
</tr>
<tr>
<td><strong>Mice</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicted</td>
<td>2.1</td>
<td>Cytotoxicity inhibition</td>
</tr>
<tr>
<td></td>
<td>1.5</td>
<td>Cytotoxicity inhibition</td>
</tr>
<tr>
<td></td>
<td>2.4</td>
<td>Cytotoxicity inhibition</td>
</tr>
<tr>
<td>In vivo</td>
<td><strong>0.84</strong></td>
<td>No. visceral contractions</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Time to death</td>
</tr>
</tbody>
</table>
Table 3. Established ED\textsubscript{50} values for the predicted in vivo dose-response data and in vivo data for mouse via oral administration. The literature reported ED\textsubscript{50} values used for comparison to the predicted ED\textsubscript{50} values are printed in bold.

<table>
<thead>
<tr>
<th>ED\textsubscript{50} (µg/kg bw)</th>
<th>Endpoint</th>
<th>Literature</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mice</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicted</td>
<td>61</td>
<td>Cytotoxicity inhibition</td>
</tr>
<tr>
<td></td>
<td>42</td>
<td>Cytotoxicity inhibition</td>
</tr>
<tr>
<td></td>
<td>69</td>
<td>Cytotoxicity inhibition</td>
</tr>
<tr>
<td>In vivo</td>
<td><strong>96</strong></td>
<td>Apathy</td>
</tr>
<tr>
<td></td>
<td>560</td>
<td>Seizures/Numbness</td>
</tr>
<tr>
<td></td>
<td>223</td>
<td>Mortality</td>
</tr>
</tbody>
</table>
**Figure Legends**

Figure 1. Structural formula of tetrodotoxin.

Figure 2. Schematic representation of the rodent PBK model for TTX.

Figure 3. Time-dependent substrate depletion of TTX in incubations with primary rat hepatocytes. Symbols represent the average ln(C_{compound}/C_{control}) at different incubation time points (mean ± SD of 3 independent experiments). Straight line represents the depletion curve and the dotted line represents zero depletion.

Figure 4. In vitro concentration response curves for the effects of TTX on (a) primary rat neonatal cortical cells in the MEA assay (circles; Kasteel and Westerink (2017) EC_{50} = 0.0055 μM, squares; Nicolas et al. (2014) EC_{50} = 0.0035 μM) and (b) neurotoxicity in mouse neuro-2a cells (squares; Hamasaki et al. (1996) EC_{50} = 0.0075 μM, inverted triangles; Nicolas et al. (2015), triangles; Yamashoji and Isshiki (2001) EC_{50} = 0.0053 μM, and circles; Yeo et al. (1996) EC_{50} = 0.0121 μM). Data points represent mean (± SD/SEM, where available).

Figure 5. Predicted concentration time curves of TTX in whole blood of rat (striped lines) dosed with TTX via (a) oral (diamonds), (b) IM (squares) and (c) IV (circles) administration. The literature data reported as plasma concentrations were adjusted to blood concentrations assuming a blood:plasma ratio of 0.42 (Hong et al. 2017). Dosage used: oral 100 μg/kg bw with 6.7% bioavailability, IM and IV 6 μg/kg bw. Data points represent mean (± SD/SEM, where available).

Figure 6. Overview of in vivo dose response data for TTX in rodents found in literature including (a) in vivo data sets for rat after TTX injection: triangles; Von Frey (g) hair test (Marcil et al. 2006) (left y-axis), squares and circles; duration of the nociceptive block (min) (Kohane et al. 1998) (right y-axis), and Kohane et al. (2000), respectively) and (b) in vivo data sets for mouse: either upon injection: circles; writhing test (Marcil et al. 2006), inverted triangles; time to death (min) (Finch et al. 2018) (left y-axis) or after oral administration: diamonds; apathy (%) (Abal et al. 2017), squares; mortality (%) (Abal et al. 2017), triangles; numbness and seizures (%) (Abal et al. 2017) (right y-axis). The red data sets present the dose-response curves for the most sensitive endpoint that were chosen for evaluation of the QIVIVE predictions. Data points represent mean (± SD/SEM, where available).

Figure 7. Predicted in vivo dose-response curve for TTX in rat upon injection (IM model) on the left y-axis compared to the in vivo data reported by Marcil et al. (2006) in the Von Frey hair test (blue line and triangles) on the right y-axis. The predictions were based on the rat MEA assay data reported by Nicolas et al. (2014) (black circles) or Kasteel and Westerink (2017) (black squares). Data points represent mean (± SD/SEM, where available).
Figure 8. Predicted in vivo dose-response curves for TTX in mice upon (a) injection (IM model) and (b) oral administration (oral model). In blue the in vivo endpoints visceral contractions (diamonds; Marcil et al. (2006)) (fig. 8a) and apathy (inverted triangles; Abal et al. (2017)) (fig 8b) displayed on right y-axes. The predictions were based on the mouse neuro-2a assay data reported by Hamasaki et al. (1996) (triangles); Yamashoji and Isshiki (2001) (circles) and Yeo et al. (1996) (squares) displayed on the left y-axes. Data points represent mean (± SD/SEM, where available).

Figure 9. In vitro concentration response curve of (a) TTX in human IPSC-derived iCell® neurons in co-culture with hIPSC-derived iCell® astrocytes in the MEA assay (Kasteel and Westerink 2017) and (b) the predicted in vivo dose-response curve acquired by PBK model facilitated reverse-dosimetry using a human oral model (b). Data points represent mean ± SEM.
Figure 1. Structural formula of tetrodotoxin.

88x52mm (300 x 300 DPI)
Figure 2. Schematic representation of the rodent PBK model for TTX.

88x74mm (300 x 300 DPI)
Figure 3. Time-dependent substrate depletion of TTX in incubations with primary rat hepatocytes. Symbols represent the average $\ln(C_{\text{compound}}/C_{\text{control}})$ at different incubation time points (mean ± SD of 3 independent experiments). Straight line represents the depletion curve and the dotted line represents zero depletion.

88x61mm (300 x 300 DPI)
Figure 4. In vitro concentration response curves for the effects of TTX on (a) primary rat neonatal cortical cells in the MEA assay (circles; Kasteel and Westerink (2017) EC50 = 0.0055 µM, squares; Nicolas et al. (2014) EC50 = 0.0035 µM) and (b) neurotoxicity in mouse neuro-2a cells (squares; Hamasaki et al. (1996) EC50 = 0.0075 µM, inverted triangles; Nicolas et al. (2015), triangles; Yamashoji and Isshiki (2001) EC50 = 0.0053 µM, and circles; Yeo et al. (1996) EC50 = 0.0121 µM). Data points represent mean (± SD/SEM, where available).

177x53mm (300 x 300 DPI)
Figure 5. Predicted concentration time curves of TTX in whole blood of rat (striped lines) dosed with TTX via (a) oral (diamonds), (b) IM (squares) and (c) IV (circles) administration. The literature data reported as plasma concentrations were adjusted to blood concentrations assuming a blood:plasma ratio of 0.42 (Hong et al. 2017). Dosage used: oral 100 µg/kg bw with 6.7% bioavailability, IM and IV 6 µg/kg bw. Data points represent mean (± SD/SEM, where available).
Figure 6. Overview of in vivo dose response data for TTX in rodents found in literature including (a) in vivo data sets for rat after TTX injection: triangles; Von Frey (g) hair test; (Marcil et al. 2006) (left y-axis), squares and circles; duration of the nociceptive block (min) (Kohane et al. 1998) (right y-axis), and Kohane et al. (2000), respectively and (b) in vivo data sets for mouse: either upon injection: circles; writhing test (Marcil et al. 2006), inverted triangles; time to death (min) (Finch et al. 2018) (left y-axis) or after oral administration: diamonds; apathy (%) (Abal et al. 2017), squares; mortality (%) (Abal et al. 2017), triangles; numbness and seizures (%) (Abal et al. 2017) (right y-axis). The red data sets present the dose-response curves for the most sensitive endpoint that were chosen for evaluation of the QIVIVE predictions. Data points represent mean (± SD/SEM, where available).
Figure 7. Predicted in vivo dose-response curve for TTX in rat upon injection (IM model) on the left y-axis compared to the in vivo data reported by Marcil et al. (2006) in the Von Frey hair test (blue line and triangles) on the right y-axis. The predictions were based on the rat MEA assay data reported by Nicolas et al. (2014) (black circles) or Kasteel and Westerink (2017) (black squares). Data points represent mean (± SD/SEM, where available).

177x71mm (300 x 300 DPI)
Figure 8. Predicted in vivo dose-response curves for TTX in mice upon (a) injection (IM model) and (b) oral administration (oral model). In blue the in vivo endpoints visceral contractions (diamonds; Marcil et al. (2006)) (fig. 8a) and apathy (inverted triangles; Abal et al. (2017)) (fig 8b) displayed on right y-axes. The predictions were based on the mouse neuro-2a assay data reported by Hamasaki et al. (1996) (triangles); Yamashoji and Isshiki (2001) (circles) and Yeo et al. (1996) (squares) displayed on the left y-axes. Data points represent mean (± SD/SEM, where available).
Figure 9. In vitro concentration response curve of (a) TTX in human IPSC-derived iCell® neurons in coculture with hIPSC-derived iCell® astrocytes in the MEA assay (Kasteel and Westerink 2017) and (b) the predicted in vivo dose-response curve acquired by PBK model facilitated reverse-dosimetry using a human oral model (b). Data points represent mean ± SEM.